Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.5098
+0.00981.96%
Post-market: 0.51000.0002+0.04%19:59 EDT
Volume:2.67M
Turnover:1.36M
Market Cap:184.29M
PE:-0.81
High:0.5262
Open:0.5001
Low:0.4980
Close:0.5000
Loading ...

BRIEF-Lexicon Announces Receipt Of Complete Response Letter For Zynquista (Sotagliflozin)

Reuters
·
21 Dec 2024

Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours

MT Newswires Live
·
21 Dec 2024

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

Reuters
·
21 Dec 2024

Lexicon receives CRL for Zynquista

TIPRANKS
·
21 Dec 2024

Lexicon Pharmaceuticals Inc - to Discontinue Zynquista Launch Preparations

THOMSON REUTERS
·
21 Dec 2024

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (Sotagliflozin)

THOMSON REUTERS
·
21 Dec 2024

Lexicon Pharmaceuticals Inc : Citigroup Cuts Target Price to $1.2 From $4

THOMSON REUTERS
·
29 Nov 2024

Lexicon price target lowered to $1.20 from $4 at Citi

TIPRANKS
·
28 Nov 2024

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
27 Nov 2024

Lexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and Restructuring

TIPRANKS
·
26 Nov 2024

Lexicon announces completion of enrollment in Phase 2B PROGRESS study

TIPRANKS
·
26 Nov 2024

BRIEF-Lexicon Announces Completion Of Enrollment In Phase 2B Progress Study Of LX9211 In Diabetic Peripheral Neuropathic Pain

Reuters
·
26 Nov 2024

Lexicon Announces Completion of Enrollment in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)

THOMSON REUTERS
·
26 Nov 2024

Lexicon Pharmaceuticals Inc - Top-Line Data From Progress Study Expected in Q1 2025

THOMSON REUTERS
·
26 Nov 2024

Lexicon Pharmaceuticals to Participate in December Investor Conferences

GlobeNewswire
·
26 Nov 2024

U.S. RESEARCH ROUNDUP-Domino's Pizza, Elastic NV, Snowflake

Reuters
·
25 Nov 2024

Lexicon Pharmaceuticals Inc : Jefferies Cuts Target Price to $0.8 From $1.4

THOMSON REUTERS
·
25 Nov 2024

Lexicon Pharmaceuticals (LXRX) Receives a Hold from Needham

TIPRANKS
·
23 Nov 2024

HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating

MT Newswires Live
·
23 Nov 2024

BUZZ-Lexicon Pharmaceuticals rises on plan to lay off 60% of employees

Reuters
·
23 Nov 2024